Related Experiment Video

Updated: Feb 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer

Margaret M Centenera1,2, Luke A Selth1,3, Esmaeil Ebrahimie3

  • 1Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide SA 5005, Australia.

Cold Spring Harbor Perspectives in Medicine
|March 14, 2018
PubMed

Insights

Genomic studies reveal how prostate cancer adapts to androgen deprivation therapy by altering androgen receptor (AR) signaling. Understanding these AR resistance mechanisms is key to developing new treatments and improving patient survival.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Metastatic prostate cancer often develops resistance to androgen deprivation therapies (ADTs).
  • Androgen receptor (AR) signaling plays a critical role in prostate cancer progression and therapeutic resistance.

Purpose of the Study:

  • To summarize the structure and function of the androgen receptor (AR).
  • To discuss the mechanisms of AR-mediated therapy resistance in prostate cancer.
  • To highlight key areas for developing novel therapeutic strategies.

Main Methods:

  • This is a review article, synthesizing existing research.
  • Genomic analyses of metastatic prostate cancer were examined.
  • AR structure, function, and resistance mechanisms were analyzed.

Main Results:

  • Genomic analyses have elucidated adaptive changes in AR signaling in resistant prostate cancer.
  • Several AR-mediated resistance mechanisms have been identified.
  • These mechanisms provide targets for novel therapeutic interventions.

Conclusions:

  • Understanding AR signaling and resistance is crucial for overcoming ADT failure.
  • New therapeutic strategies targeting AR are needed to improve outcomes for metastatic prostate cancer patients.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Published on: October 20, 2015

14.6K

Related Concept Videos

Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
7
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
111.5K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.8K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.2K